IMPORTANT NOTICE: Our email addresses will soon change. Learn more >>

Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.
Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  2. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  3. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  4. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  5. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  6. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  7. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  8. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  9. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  10. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  11. Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed
  12. Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed
  13. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  14. Gideon HP, et al. 2022. Immunity. 55:827. PubMed
  15. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  16. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  17. Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed
  18. Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed
  19. Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed
  20. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  21. Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed
  22. Zhu Y, et al. 2022. Immunology. 167:576. PubMed
  23. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  24. Wang Z, et al. 2022. J Exp Med. 219: . PubMed
  25. Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed
  26. Buckner CM, et al. 2022. Cell. 185:4333. PubMed
  27. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  28. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  29. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  30. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  31. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  32. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  33. Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed
  34. Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed
  35. Pleuger C, et al. 2022. Elife. 11: . PubMed
  36. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  37. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  38. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  39. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  40. Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed
  41. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  42. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  43. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  44. Rosain J, et al. 2023. Cell. 186:621. PubMed
  45. Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed
  46. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  47. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  48. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  49. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  50. Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed
  51. Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed
  52. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  53. Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed
  54. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  55. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  56. Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed
  57. Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed
  58. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  59. Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed
  60. Zhao Y, et al. 2022. J Neurosci. . PubMed
  61. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  62. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  63. Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed
  64. Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed
  65. Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed
  66. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  67. Han X, et al. 2022. Nutrients. 14:. PubMed
  68. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  69. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  70. Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed
  71. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  72. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  73. Muri J, et al. 2023. Nat Immunol. 24:604. PubMed
  74. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  75. Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed
  76. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
  77. Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed
  78. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  79. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  80. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  81. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  82. Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed
  83. Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed
  84. Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed
  85. Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed
  86. Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed
  87. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  88. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  89. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  90. Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed
  91. Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed
  92. Imai H, et al. 2023. iScience. 26:106822. PubMed
  93. Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed
  94. Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed
  95. Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed
  96. Wu L, et al. 2023. Cell Res. . PubMed
  97. Cansever D, et al. 2023. Nat Immunol. . PubMed
  98. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  99. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  100. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  101. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  102. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  103. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  104. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  105. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  106. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  107. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  108. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  109. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  110. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  111. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  112. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  113. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  114. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  115. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  116. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  117. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  118. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  119. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  120. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  121. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  122. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  123. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  124. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  125. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  126. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  127. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  128. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  129. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  130. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  131. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  132. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  133. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  134. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  135. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  136. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  137. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  138. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  139. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  140. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  141. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  142. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  143. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  144. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  145. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  146. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  147. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  148. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  149. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  150. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  151. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  152. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  153. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  154. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  155. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  156. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  157. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  158. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  159. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  160. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  161. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  162. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  163. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  164. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  165. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  166. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  167. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  168. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  169. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  170. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  171. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  172. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  173. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  174. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  175. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  176. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  177. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  178. Woodruff MC, et al. 2022. Nature. :. PubMed
  179. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  180. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  181. Akiyama H, et al. 2020. J Virol. . PubMed
  182. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  183. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  184. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  185. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  186. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  187. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  188. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  189. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  190. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  191. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  192. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  193. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  194. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  195. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  196. Mills C, et al. 2022. Cells. 11:. PubMed
  197. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  198. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  199. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  200. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  201. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  202. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  203. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  204. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  205. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  206. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  207. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  208. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  209. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  210. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  211. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  212. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  213. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  214. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  215. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  216. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  217. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  218. Wang Z, et al. 2021. bioRxiv. . PubMed
  219. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  220. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  221. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  222. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  223. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  224. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  225. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  226. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  227. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  228. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  229. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  230. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  231. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  232. Woodruff M, et al. 2020. medRxiv. . PubMed
  233. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  234. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  235. English KG, et al. 2022. Biomedicines. 10:. PubMed
  236. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  237. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  238. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  239. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  240. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  241. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  242. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  243. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  244. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  245. Popay TM, et al. 2021. Elife. 10: . PubMed
  246. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  247. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  248. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  249. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  250. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  251. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  252. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  253. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  254. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  255. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  256. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  257. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  258. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  259. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  260. Ito Y, et al. 2018. Cell. 174:636. PubMed
  261. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  262. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  263. Elias G, et al. 2022. Elife. 11:. PubMed
  264. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  265. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  266. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  267. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  268. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  269. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  270. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  271. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  272. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  273. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  274. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  275. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  276. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  277. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  278. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  279. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  280. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  281. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  282. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  283. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  284. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  285. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  286. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  287. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  288. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  289. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  290. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  291. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  292. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  293. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  294. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  295. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  296. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  297. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  298. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  299. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  300. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  301. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  302. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  303. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  304. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  305. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  306. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  307. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  308. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  309. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  310. Wang Z, et al. 2021. Nature. 592:616. PubMed
  311. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  312. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  313. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  314. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  315. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  316. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  317. Dudek M, et al. 2021. Nature. 592:444. PubMed
  318. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  319. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  320. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  321. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  322. He Y, et al. 2022. Cells. 11:. PubMed
  323. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  324. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  325. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  326. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  327. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  328. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  329. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  330. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  331. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  332. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  333. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  334. Wang Z, et al. 2021. Nature. 595:426. PubMed
  335. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  336. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  337. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  338. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  339. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  340. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  341. Korin B, et al. 2020. Sleep. :43. PubMed
  342. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  343. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  344. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  345. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  346. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  347. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  348. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  349. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  350. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  351. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  352. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  353. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  354. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  355. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  356. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  357. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  358. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  359. Gaebler C, et al. 2020. bioRxiv. . PubMed
  360. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  361. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  362. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  363. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  364. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  365. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  366. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  367. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  368. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  369. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  370. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  371. Viant C, et al. 2020. Cell. 183:1298. PubMed
  372. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  373. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  374. Sibler E, et al. 2021. Cells. 10:. PubMed
  375. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  376. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  377. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  378. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  379. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  380. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  381. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  382. Spath S, et al. 2022. iScience. 25:104998. PubMed
  383. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  384. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  385. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
  386. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed
  387. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  388. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed
  389. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  390. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  391. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  392. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  393. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  394. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  395. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  396. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  397. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  398. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  399. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  400. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 7    Revision Date: 12/18/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account